Entrada Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $213.4M
- Price
- $5.48
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.86%
- Volume
- 463.8K
About
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Quick stats
Shares outstanding38.9M
Computed float22.2M
Float / shares57.1%
Cash runway (months)15.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001689375
Websitehttps://www.entradatx.com
AI Summary
AI-generated1/32
minorneutralother
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Entrada Therapeutics named Parent Project Muscular Dystrophy (U.S.) and Duchenne Parent Project Netherlands as recipients of its fourth annual DREAMS Grant Program, which awards two $50,000 grants to non-profits serving underrepresented parts of the Duchenne muscular dystrophy community.
An independent review committee of neuromuscular specialists, patient advocates and health equity advocates selected the recipients, whose projects focus on expanding equitable access to specialized Duchenne care for adults, rural and underserved populations.
CEO Dipal Doshi tied the awards to this year's World Duchenne Awareness Day theme of 'access changes lives,' positioning the grants as models for improving Duchenne care delivery across borders.
The release is community-relations news aligned with Entrada's Duchenne-focused pipeline (including lead exon-skipping programs and partnered VX-670) and carries no direct financial or clinical impact on the company.